Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Miladys Santos

Physician Assistant New York, NY Physician Assistant

NPI 1780864355 CMS profile 10567944

462 1St Ave, New York, NY 10016

Open in the dashboard

General payments

$17,719

583 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miladys Santos of New York, NY is reported in the CMS Open Payments database as having received $17,719 across 583 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,560 101
2024 General $2,893 114
2023 General $3,443 123
2022 General $5,669 145
2021 General $3,155 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miladys Santos
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Miladys Santos were reported at $2,560. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Miladys Santos Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,155 $132 $37–$438 $132
2022 $5,669 $155 $48–$522 $149
2023 $3,443 $167 $52–$557 $160
2024 $2,893 $178 $55–$600 $164
2025 $2,560 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $4,204 131 payments
  2. AstraZeneca Pharmaceuticals LP $3,478 69 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $1,438 61 payments
  4. Novo Nordisk Inc $1,269 48 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $908 47 payments
  6. Amgen Inc. $882 22 payments
  7. Lilly USA, LLC $841 32 payments
  8. GlaxoSmithKline, LLC. $615 28 payments
  9. Esperion Therapeutics, Inc. $551 9 payments
  10. Amarin Pharma Inc. $540 28 payments
  11. Other $2,993 108 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,719 583 payments
Products named General payments · program years 2021–2025
  1. BREZTRI $1,876 39 payments
  2. VRAYLAR $1,816 72 payments
  3. CREON $1,171 17 payments
  4. OFEV $1,074 48 payments
  5. FARXIGA $1,071 21 payments
  6. RYBELSUS $1,003 40 payments
  7. XIFAXAN $842 44 payments
  8. Ozempic $753 38 payments
  9. TRELEGY ELLIPTA $602 27 payments
  10. MOUNJARO $575 20 payments
  11. Other $11,209 410 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

5,117

Median for Physician Assistant: 241

Drug cost

$515,416

Median for Physician Assistant: $4,110

Branded share of claims

27.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 103 $89,630
Vascepa Icosapent Ethyl Brand 197 $84,926
Ozempic Semaglutide Brand 37 $44,553
Jardiance Empagliflozin Brand 41 $41,481
Januvia Sitagliptin Phosphate Brand 30 $39,708
Linzess Linaclotide Brand 60 $35,539
Janumet Sitagliptin Phos/Metformin Hcl Brand 50 $30,662
Vraylar Cariprazine Hcl Brand 16 $21,218
Eliquis Apixaban Brand 12 $16,786
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 19 $13,718

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $505
$505 16 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $331
$331 19 —
CREON
  • AbbVie, Inc. $140
$140 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $139
$139 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $80
  • Lilly USA, LLC $43
$124 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

583 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record